OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Gitanjali Srivastava, Caroline M. Apovian
Current Obesity Reports (2018) Vol. 7, Iss. 2, pp. 147-161
Closed Access | Times Cited: 211
Gitanjali Srivastava, Caroline M. Apovian
Current Obesity Reports (2018) Vol. 7, Iss. 2, pp. 147-161
Closed Access | Times Cited: 211
Showing 1-25 of 211 citing articles:
Metabolically Healthy Obesity
Matthias Blüher
Endocrine Reviews (2020) Vol. 41, Iss. 3
Open Access | Times Cited: 718
Matthias Blüher
Endocrine Reviews (2020) Vol. 41, Iss. 3
Open Access | Times Cited: 718
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 683
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 683
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Young Jin Tak, Sang Yeoup Lee
Current Obesity Reports (2021) Vol. 10, Iss. 1, pp. 14-30
Open Access | Times Cited: 261
Young Jin Tak, Sang Yeoup Lee
Current Obesity Reports (2021) Vol. 10, Iss. 1, pp. 14-30
Open Access | Times Cited: 261
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 228
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 228
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
Steven B. Heymsfield, Laura A. Coleman, Ram R. Miller, et al.
JAMA Network Open (2021) Vol. 4, Iss. 1, pp. e2033457-e2033457
Open Access | Times Cited: 177
Steven B. Heymsfield, Laura A. Coleman, Ram R. Miller, et al.
JAMA Network Open (2021) Vol. 4, Iss. 1, pp. e2033457-e2033457
Open Access | Times Cited: 177
Biological Properties and Bioactive Components of Allium cepa L.: Focus on Potential Benefits in the Treatment of Obesity and Related Comorbidities
Mariangela Marrelli, Valentina Amodeo, Giancarlo Statti, et al.
Molecules (2018) Vol. 24, Iss. 1, pp. 119-119
Open Access | Times Cited: 166
Mariangela Marrelli, Valentina Amodeo, Giancarlo Statti, et al.
Molecules (2018) Vol. 24, Iss. 1, pp. 119-119
Open Access | Times Cited: 166
Emerging role of carbonic anhydrase inhibitors
Claudiu T. Supuran
Clinical Science (2021) Vol. 135, Iss. 10, pp. 1233-1249
Closed Access | Times Cited: 156
Claudiu T. Supuran
Clinical Science (2021) Vol. 135, Iss. 10, pp. 1233-1249
Closed Access | Times Cited: 156
Stimulus-cleavable chemistry in the field of controlled drug delivery
Yufei Xue, Hua Bai, Bo Peng, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 8, pp. 4872-4931
Closed Access | Times Cited: 125
Yufei Xue, Hua Bai, Bo Peng, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 8, pp. 4872-4931
Closed Access | Times Cited: 125
BATMAN-TCM 2.0: an enhanced integrative database for known and predicted interactions between traditional Chinese medicine ingredients and target proteins
Xiangren Kong, Chao Liu, Zuzhen Zhang, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1110-D1120
Open Access | Times Cited: 53
Xiangren Kong, Chao Liu, Zuzhen Zhang, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1110-D1120
Open Access | Times Cited: 53
The Interplay between Obesity and Inflammation
Ilinca Savulescu‐Fiedler, R. Mihalcea, Şerban Dragosloveanu, et al.
Life (2024) Vol. 14, Iss. 7, pp. 856-856
Open Access | Times Cited: 23
Ilinca Savulescu‐Fiedler, R. Mihalcea, Şerban Dragosloveanu, et al.
Life (2024) Vol. 14, Iss. 7, pp. 856-856
Open Access | Times Cited: 23
Effectiveness and safety of drugs for obesity
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 22
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 22
Semaglutide as a promising antiobesity drug
Georgios A. Christou, Niki Katsiki, John E. Blundell, et al.
Obesity Reviews (2019) Vol. 20, Iss. 6, pp. 805-815
Closed Access | Times Cited: 124
Georgios A. Christou, Niki Katsiki, John E. Blundell, et al.
Obesity Reviews (2019) Vol. 20, Iss. 6, pp. 805-815
Closed Access | Times Cited: 124
Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives
Walter Cabri, Paolo Cantelmi, Dario Corbisiero, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 93
Walter Cabri, Paolo Cantelmi, Dario Corbisiero, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 93
Amylin Analog Pramlintide Induces Migraine‐like Attacks in Patients
Hashmat Ghanizada, Mohammad Al‐Mahdi Al‐Karagholi, Christopher S. Walker, et al.
Annals of Neurology (2021) Vol. 89, Iss. 6, pp. 1157-1171
Open Access | Times Cited: 82
Hashmat Ghanizada, Mohammad Al‐Mahdi Al‐Karagholi, Christopher S. Walker, et al.
Annals of Neurology (2021) Vol. 89, Iss. 6, pp. 1157-1171
Open Access | Times Cited: 82
Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes
Geetanjali Sharma, Chelin Hu, Daniela I. Staquicini, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 528
Open Access | Times Cited: 81
Geetanjali Sharma, Chelin Hu, Daniela I. Staquicini, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 528
Open Access | Times Cited: 81
Genetic Determinants of Childhood Obesity
Sheridan H. Littleton, Robert I. Berkowitz, Struan F.A. Grant
Molecular Diagnosis & Therapy (2020) Vol. 24, Iss. 6, pp. 653-663
Open Access | Times Cited: 81
Sheridan H. Littleton, Robert I. Berkowitz, Struan F.A. Grant
Molecular Diagnosis & Therapy (2020) Vol. 24, Iss. 6, pp. 653-663
Open Access | Times Cited: 81
Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control
Paul El Meouchy, Mohamad Wahoud, Sabine Allam, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12305-12305
Open Access | Times Cited: 64
Paul El Meouchy, Mohamad Wahoud, Sabine Allam, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12305-12305
Open Access | Times Cited: 64
Photo-induced radical thiol–ene chemistry: a versatile toolbox for peptide-based drug design
Marzieh Ahangarpour, Iman Kavianinia, Paul W. R. Harris, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 2, pp. 898-944
Closed Access | Times Cited: 61
Marzieh Ahangarpour, Iman Kavianinia, Paul W. R. Harris, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 2, pp. 898-944
Closed Access | Times Cited: 61
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 47
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 47
The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies
Elisabet Jerlhag
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 36
Elisabet Jerlhag
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 36
Cellular and Molecular Mechanisms Associating Obesity to Bone Loss
Yasmin Silva Forte, Mariana Renovato‐Martins, Christina Barja‐Fidalgo
Cells (2023) Vol. 12, Iss. 4, pp. 521-521
Open Access | Times Cited: 29
Yasmin Silva Forte, Mariana Renovato‐Martins, Christina Barja‐Fidalgo
Cells (2023) Vol. 12, Iss. 4, pp. 521-521
Open Access | Times Cited: 29
Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
POTENTIAL ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS IN SUBSTANCE USE DISORDER: A SYSTEMATIC REVIEW OF RANDOMIZED TRIALS
Silvia Martinelli, Alessandro Mazzotta, Mattia Longaroni, et al.
Drug and Alcohol Dependence (2024) Vol. 264, pp. 112424-112424
Open Access | Times Cited: 9
Silvia Martinelli, Alessandro Mazzotta, Mattia Longaroni, et al.
Drug and Alcohol Dependence (2024) Vol. 264, pp. 112424-112424
Open Access | Times Cited: 9
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Hypoxia Inducible Factor as a Central Regulator of Metabolism – Implications for the Development of Obesity
Joana M. Gaspar, Lı́cio A. Velloso
Frontiers in Neuroscience (2018) Vol. 12
Open Access | Times Cited: 80
Joana M. Gaspar, Lı́cio A. Velloso
Frontiers in Neuroscience (2018) Vol. 12
Open Access | Times Cited: 80
